Trial Profile

Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SenL-T7 (Primary) ; Cyclophosphamides; Fludarabine
Indications Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

13 Jun 2024 Status changed from recruiting to completed.
12 Dec 2023 Results (n=10) investigating the safety and efficacy of CAR-T therapy for treating r/r AML patients with CD7-positive disease presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Results (n=11)assessing safety and efficacy of CD7 CAR-T therapy in treating refractory/relapsed MPAL adult patients withCD7-positive, presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com